Middle East & Africa Precision Oncology Market Size & Outlook
Middle East & Africa precision oncology market, 2018-2030 (US$M)
Related Markets
MEA precision oncology market highlights
- The MEA precision oncology market generated a revenue of USD 3,569.1 million in 2024.
- The market is expected to grow at a CAGR of 3.5% from 2025 to 2030.
- In terms of segment, therapeutics was the largest revenue generating product in 2024.
- Diagnostics is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, South Africa is expected to register the highest CAGR from 2025 to 2030.
MEA data book summary
| Market revenue in 2024 | USD 3,569.1 million |
| Market revenue in 2030 | USD 4,454.2 million |
| Growth rate | 3.5% (CAGR from 2025 to 2030) |
| Largest segment | Therapeutics |
| Fastest growing segment | Diagnostics |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Diagnostics, Therapeutics |
| Key market players worldwide | Thermo Fisher Scientific Inc, Invitae Corp, Qiagen NV, Illumina Inc, Exact Sciences Corp, Rain Oncology, Strata Oncology, Xilis, Variantyx, BioServe, Relay Therapeutics, Acrivon Therapeutics |
Other key industry trends
- In terms of revenue, MEA region accounted for 3.1% of the global precision oncology market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 50,287.5 million by 2030.
Therapeutics was the largest segment with a revenue share of 74.54% in 2024. Horizon Databook has segmented the Middle East & Africa precision oncology market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
The precision oncology market in the Middle East and Africa is expected to grow at the fastest CAGR during the forecast period, due to several driving factors. Increasing availability of innovative cancer therapies through strategic collaborations contributes to the region’s growth. For instance, in November 2024, Pharmaceuticals entered into a collaboration with Pharmalink. With this partnership, Pharmalink received the commercial rights for sugemalimab, an advanced anti-cancer therapy, across key countries in the MENA region and South Africa.
This agreement not only ensures the supply and commercialization of sugemalimab but also accelerates access to cutting-edge treatments in countries like Saudi Arabia, UAE, Egypt, and South Africa. Such collaborations are bolstering the precision oncology ecosystem by addressing unmet medical needs and improving cancer care outcomes across the region.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Precision Oncology Market Scope
Precision Oncology Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
MEA precision oncology market size, by country, 2018-2030 (US$M)
Middle East & Africa Precision Oncology Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
